Boston Scientific Sees Unusually Large Options Volume (NYSE:BSX)

Boston Scientific Co. (NYSE:BSX) was the target of unusually large options trading on Thursday. Stock traders purchased 17,026 call options on the stock. This is an increase of approximately 161% compared to the typical volume of 6,534 call options.

Boston Scientific Trading Up 1.9 %

Shares of BSX opened at $74.10 on Friday. Boston Scientific has a one year low of $48.35 and a one year high of $74.39. The stock has a 50-day moving average price of $68.79 and a 200 day moving average price of $61.81. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.14 and a current ratio of 1.66. The company has a market capitalization of $108.71 billion, a P/E ratio of 62.27, a P/E/G ratio of 2.51 and a beta of 0.77.

Insider Transactions at Boston Scientific

In other news, Director Charles J. Dockendorff sold 3,946 shares of the stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $72.70, for a total value of $286,874.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, Director Charles J. Dockendorff sold 3,946 shares of the company’s stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $72.70, for a total value of $286,874.20. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Daniel J. Brennan sold 13,662 shares of Boston Scientific stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $65.86, for a total value of $899,779.32. Following the sale, the chief financial officer now owns 271,542 shares of the company’s stock, valued at approximately $17,883,756.12. The disclosure for this sale can be found here. Insiders sold 82,330 shares of company stock valued at $5,682,434 in the last 90 days. 0.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Pinnacle Associates Ltd. raised its stake in Boston Scientific by 2.0% during the first quarter. Pinnacle Associates Ltd. now owns 7,478 shares of the medical equipment provider’s stock worth $512,000 after acquiring an additional 148 shares during the period. KCM Investment Advisors LLC lifted its holdings in shares of Boston Scientific by 1.7% in the 1st quarter. KCM Investment Advisors LLC now owns 9,225 shares of the medical equipment provider’s stock worth $632,000 after purchasing an additional 150 shares during the last quarter. Hazlett Burt & Watson Inc. lifted its holdings in shares of Boston Scientific by 24.0% in the 1st quarter. Hazlett Burt & Watson Inc. now owns 826 shares of the medical equipment provider’s stock worth $57,000 after purchasing an additional 160 shares during the last quarter. BSW Wealth Partners grew its stake in Boston Scientific by 2.3% during the 4th quarter. BSW Wealth Partners now owns 7,398 shares of the medical equipment provider’s stock worth $428,000 after buying an additional 165 shares during the last quarter. Finally, Allstate Corp increased its position in Boston Scientific by 2.9% in the fourth quarter. Allstate Corp now owns 5,938 shares of the medical equipment provider’s stock worth $343,000 after buying an additional 165 shares during the period. Institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on BSX shares. Mizuho lifted their target price on shares of Boston Scientific from $80.00 to $85.00 and gave the stock a “buy” rating in a research note on Thursday, April 25th. Citigroup raised their price target on Boston Scientific from $79.00 to $85.00 and gave the stock a “buy” rating in a research note on Thursday, April 25th. Evercore ISI upped their price objective on shares of Boston Scientific from $72.00 to $78.00 and gave the company an “outperform” rating in a research note on Thursday, April 25th. Deutsche Bank Aktiengesellschaft raised their target price on shares of Boston Scientific from $63.00 to $73.00 and gave the stock a “hold” rating in a research report on Thursday, April 25th. Finally, Robert W. Baird upped their price target on shares of Boston Scientific from $79.00 to $84.00 and gave the stock an “outperform” rating in a research report on Thursday, April 25th. Three analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Boston Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $75.09.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.